Publications by authors named "H Skali"
Background: This study aims to characterize right ventricular dysfunction (RVD) in heart failure (HF) with preserved ejection fraction and understand the cumulative prognostic value of abnormal RV echocardiographic parameters in HF with preserved ejection fraction.
Methods And Results: Data from 809 patients in the PARAGON-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With Angiotensin-Receptor Blocker Global Outcomes in HF With Preserved Ejection Fraction) echocardiographic substudy (55% women, mean age 74±8 years) were analyzed. Correlates of RVD (defined as tricuspid annular plane systolic excursion <1.
Aims: To evaluate clinical outcomes, echocardiographic features, and the efficacy and safety of sacubitril/valsartan compared to valsartan across age groups in the PARAGON-HF trial.
Methods And Results: A total of 4796 participants ≥50 years of age with chronic heart failure (HF) and left ventricular ejection fraction (LVEF) ≥45% were divided into three age groups: <65 years (n = 825), 65-74 years (n = 1772), and ≥75 years (n = 2199). Echocardiograms of 1097 patients were analysed in a standardized fashion at a core imaging laboratory.
Article Synopsis
- The study investigates how bone marrow-derived pro-inflammatory macrophages and embryo-derived reparative macrophages impact progressive heart failure with reduced ejection fraction (HFrEF) and explores the potential of mesenchymal precursor cells (MPCs) to improve patient outcomes.
- In the DREAM-HF trial, significant risk factors for cardiovascular death (CVD) were identified in patients with HFrEF, particularly inflammation and ischaemic aetiology, which increased the risk by 61% and 38%, respectively.
- The introduction of MPCs led to notable reductions in major adverse cardiovascular events (MACE) by 88% and 52% over a 30-month follow-up in patients with ischaemic HFrEF and inflammation.
Article Synopsis
- N-terminal pro-B-type natriuretic peptides (NT-proBNPs) are important biomarkers for evaluating heart failure risk, but their levels can be misleading in patients with chronic kidney disease due to the kidney’s impact on eGFR.
- This study aimed to analyze the relationship between NT-proBNP levels and cardiovascular outcomes, specifically hospitalizations and deaths, in heart failure patients with varying kidney function.
- In a large cohort of over 14,000 patients, the results indicated that NT-proBNP levels significantly increased with lower eGFR levels, and every doubling of NT-proBNP was linked to a 37% higher risk of adverse cardiovascular outcomes.